ADA (American Diabetes Association) June 20-23 Obesity Medicines Novo Nordisk Posters and Talks
Novo CagriSema CagriSema is an investigational medication being developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. It is a fixed-dose combination of two drugs: Cagrilintide: An amylin analog that helps regulate appetite and reduce food intake Semaglutide: A glucagon-like peptide-1 (GLP-1) receptor agonist that improves blood sugar control and promotes weight loss. CagriSema is designed […]
STAT+: Pharmalittle: We’re reading about a Lilly deal, a gene therapy shock for Duchenne families, and more
Top of the morning to you. Unfortunately, soggy gray skies are enveloping the placid Pharmalot campus, but our spirits remain decidedly sunny, nonetheless. Why? We will trot out a bit of wisdom from the dearly departed Morning Mayor, who taught us that “every new day should be unwrapped like a precious gift.” While you tug […]
Renewing the Ozempic Patent in Canada Costs Very Little. Surprisingly, Novo Nordisk Has Chosen Not to
Novo Nordisk is the Danish pharmaceutical company that developed semaglutide, the active ingredient in the widely-used Ozempic medication. Notably, the company has failed to pay the maintenance fee for its patent for several years. A million-worth oversight. According to a Science article, Novo Nordisk hasn’t paid the maintenance fee for the semaglutide patent, which currently […]
GLP-1 Drugs Like Ozempic Are Widely Popular. Here Are Side Effects You Should Know About
Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side effects you should know about.
Oral Semaglutide: Trends Suggest Potential Kidney Benefits
While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn’t match the effects seen with the injectable formulation in the FLOW trial, the observed trends suggest improvements. Medscape Medical News
Lark Health unveils LarkVantage, an AI-powered tool to manage GLP-1 costs – Fierce Healthcare
Lark Health unveils LarkVantage, an AI-powered tool to manage GLP-1 costs Fierce Healthcare
Bariatric Surgery Beats GLP-1 RAs for Sustained Weight Loss
Bariatric surgery is associated with a significantly greater long-term weight loss than treatment with GLP-1 receptor agonists, a new head-to-head real-world study finds. Medscape Medical News
Uncovering unexpected impacts of popular GLP-1 diabetes drugs
GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for vigilance regarding new health risks.
Men Are Reporting ‘Ozempic Penis’ – But Experts Say It’s Not What They Think
Man wearing a belt Recently, Redditors in an Ozempic forum shared an unexpected perceived side-effect of taking the semaglutide jab. “Increased size, anyone else notice?” the site user wrote. In the comments, multiple site users confirmed they’d also seen change, which some have called “Ozempic penis.” They’re not alone. Diabetes.co.uk suggested that the 10% increase […]
STAT+: Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion
Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease. Lilly will acquire Verve for $10.50 per share, a premium of nearly 70% to the biotech’s share price at Monday’s close. The deal also includes an additional payment of $3 per share contingent on the first patient […]